{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:50:06Z","timestamp":1790704206931,"version":"4.1.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2002,5,1]],"date-time":"2002-05-01T00:00:00Z","timestamp":1020211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2002,5]]},"DOI":"10.1002\/jps.3000","type":"journal-article","created":{"date-parts":[[2002,8,25]],"date-time":"2002-08-25T23:45:33Z","timestamp":1030319133000},"page":"1334-1342","source":"Crossref","is-referenced-by-count":50,"title":["Pharmacodynamic Interaction of Recombinant Human Interleukin-10 and Prednisolone Using in vitro Whole Blood Lymphocyte Proliferation"],"prefix":"10.1016","volume":"91","author":[{"given":"Abhijit","family":"Chakraborty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Jusko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1002\/jps.3000_bb0010","first-page":"1263","article-title":"Prospects for synergistic immunosuppressive drug therapy in the coming decade","volume":"24","author":"Kahan","year":"1992","journal-title":"Transplant Proc"},{"key":"10.1002\/jps.3000_bb0015","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1002\/j.1875-9114.1996.tb03638.x","article-title":"Immunopharmacologic therapy in renal transplantation","volume":"16","author":"Shoker","year":"1996","journal-title":"Pharmacotherapy"},{"key":"10.1002\/jps.3000_bb0020","first-page":"191","article-title":"Species- and gender-related differences in cyclosporine\/prednisolone\/sirolimus interactions in whole blood lymphocyte proliferation assays","volume":"286","author":"Ferron","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1002\/jps.3000_bb0025","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S1081-1206(10)63052-9","article-title":"Interleukin-10: Biology, role in inflammation and autoimmunity","volume":"79","author":"Lalani","year":"1997","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1002\/jps.3000_bb0030","doi-asserted-by":"crossref","first-page":"811","DOI":"10.4049\/jimmunol.153.2.811","article-title":"IL-10 inhibits transcription of cytokine genes in human peripheral blood mononuclear cells","volume":"153","author":"Wang","year":"1994","journal-title":"J Immunol"},{"key":"10.1002\/jps.3000_bb0035","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1182\/blood.V81.11.2964.bloodjournal81112964","article-title":"Human interleukin-10 can directly inhibit T-cell growth","volume":"81","author":"Taga","year":"1993","journal-title":"Blood"},{"key":"10.1002\/jps.3000_bb0040","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1177\/00912709922008137","article-title":"Pharmacokinetic and adrenal interactions of interleukin-10 and prednisone in healthy volunteers","volume":"39","author":"Chakraborty","year":"1999","journal-title":"J Clin Pharmacol"},{"key":"10.1002\/jps.3000_bb0045","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/342082a0","article-title":"Interleukin-2-dependent autocrine proliferation in T-cell development","volume":"342","author":"Toribio","year":"1989","journal-title":"Nature"},{"key":"10.1002\/jps.3000_bb0050","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.4049\/jimmunol.148.4.1143","article-title":"IL-10 inhibits human T cell proliferation and IL-2 production","volume":"148","author":"Taga","year":"1992","journal-title":"J Immunol"},{"key":"10.1002\/jps.3000_bb0055","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.4049\/jimmunol.123.4.1624","article-title":"Glucocorticoid-induced inhibition of T cell growth factor production I. The effect on mitogen-induced lymphocyte proliferation","volume":"123","author":"Gillis","year":"1979","journal-title":"J Immunol"},{"key":"10.1002\/jps.3000_bb0060","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose\u2013effect relationships: The combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv Enzyme Regul"},{"key":"10.1002\/jps.3000_bb0065","first-page":"187","article-title":"Combination chemotherapy in vitro with adriamycin. Observations of additive, antagonistic, and synergistic effects when used in two-drug combinations on cultured human lymphoma cells","volume":"1","author":"Drewinko","year":"1976","journal-title":"Can Biochem Biophys"},{"key":"10.1002\/jps.3000_bb0070","series-title":"Drug interactions","first-page":"349","article-title":"The isobolographic method applied to drug interactions","author":"Gessner","year":"1974"},{"key":"10.1002\/jps.3000_bb0075","first-page":"5318","article-title":"Application of a new approach for the quantitation of drug synergism to the combination of cis-diamminedichloroplatinum and 1-beta-D-arabinofuranosylcytosine","volume":"50","author":"Greco","year":"1990","journal-title":"Cancer Res"},{"key":"10.1002\/jps.3000_bb0080","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.2042-7158.1964.tb07437.x","article-title":"A molecular basis for drug action","volume":"16","author":"Ariens","year":"1964","journal-title":"J Pharm Pharmacol"},{"key":"10.1002\/jps.3000_bb0085","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2042-7158.1964.tb07461.x","article-title":"A molecular basis for drug action. The interaction of one or more drugs with different receptors","volume":"16","author":"Ariens","year":"1964","journal-title":"J Pharm Pharmacol"},{"key":"10.1002\/jps.3000_bb0090","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3109\/08923979409007100","article-title":"Inhibition of phytohaemagglutinin-induced lymphocyte proliferation by immunosuppressive drugs: Use of whole blood culture","volume":"16","author":"Piekoszewski","year":"1994","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"10.1002\/jps.3000_bb0095","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/00007691-198802000-00001","article-title":"Kinetics of drug effects in man","volume":"10","author":"Oosterhuis","year":"1988","journal-title":"Ther Drug Monit"},{"key":"10.1002\/jps.3000_bb0100","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/BF02353790","article-title":"Pharmacodynamic model for joint exogenous and endogenous corticosteroid suppression of lymphocyte trafficking","volume":"22","author":"Milad","year":"1994","journal-title":"J Pharmacokin Biopharm"},{"key":"10.1002\/jps.3000_bb0105","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S0009-9236(99)70110-4","article-title":"Pharmacoimmunodynamic interactions of interleukin-10 and prednisone in healthy volunteers","volume":"65","author":"Chakraborty","year":"1999","journal-title":"Clin Pharmacol Ther"},{"key":"10.1002\/jps.3000_bb0110","series-title":"ADAPT II users guide: Pharmacokinetic\/pharmacodynamic systems analysis software","author":"D'Argenio","year":"1997"},{"key":"10.1002\/jps.3000_bb0115","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/clpt.1993.167","article-title":"Gender-based effects on methylprednisolone pharmacokinetics and pharmacodynamics","volume":"54","author":"Lew","year":"1993","journal-title":"Clin Pharmacol Ther"},{"key":"10.1002\/jps.3000_bb0120","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1053\/gast.2000.20229","article-title":"Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group","volume":"119","author":"Fedorak","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1002\/jps.3000_bb0125","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1126\/science.270.5234.286","article-title":"Immunosuppression by glucocorticoids: Inhibition of NF-kappa B activity through induction of I kappa B synthesis","volume":"270","author":"Auphan","year":"1995","journal-title":"Science"},{"key":"10.1002\/jps.3000_bb0130","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1126\/science.270.5234.283","article-title":"Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids","volume":"270","author":"Scheinman","year":"1995","journal-title":"Science"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354916310012?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354916310012?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,12,29]],"date-time":"2023-12-29T23:12:16Z","timestamp":1703891536000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354916310012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,5]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2002,5]]}},"alternative-id":["S0022354916310012"],"URL":"https:\/\/doi.org\/10.1002\/jps.3000","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2002,5]]}}}